Home
Random
Log in
Settings
About Azupedia
Disclaimers
Azupedia
Search
Translations
:
Sitagliptin/22/en
Language
Watch
View source
v
t
e
Oral
diabetes medication
,
insulins
and
insulin analogs
, and other drugs used in diabetes (
A10
)
Insulins
/
insulin analogs
fast-acting
Insulin aspart
Insulin glulisine
Insulin lispro
short-acting
Regular insulin
#
long-acting
Insulin detemir
#
Insulin glargine
#
(
+lixisenatide
)
NPH insulin
Lente insulin
‡
Ultralente insulin
‡
ultra-long-acting
Insulin degludec
#
(
+insulin aspart
,
+liraglutide
)
Insulin icodec
†
(
+semaglutide
)
inhalable
Exubera
‡
Afrezza
#
WHO-EM
‡
Withdrawn
from market
Clinical trials
:
†
Phase III
§
Never to phase III
Non-insulins
Insulin sensitizers
Biguanides
Buformin
‡
Metformin
#
Phenformin
‡
TZDs
/"glitazones" (
PPAR
)
Ciglitazone
§
Darglitazone
§
Englitazone
§
Lobeglitazone
Netoglitazone
§
Pioglitazone
Rivoglitazone
†
Rosiglitazone
Troglitazone
‡
Dual PPAR agonists
Aleglitazar
†
Muraglitazar
§
Saroglitazar
Tesaglitazar
§
Amylin
analogs and
DACRAs
Cagrilintide
§
Pramlintide
Secretagogues
K
+
ATP
Sulfonylureas
1st generation
:
Acetohexamide
Carbutamide
Chlorpropamide
Glycyclamide
Metahexamide
Tolazamide
Tolbutamide
2nd generation
:
Glibenclamide (glyburide)
Glibornuride
Glicaramide
Gliclazide
#
Glimepiride
Glipizide
Gliquidone
Glisoxepide
Glyclopyramide
Meglitinides
/"glinides"
Mitiglinide
Nateglinide
Repaglinide
GLP-1 receptor agonists
Albiglutide
‡
Danuglipron
†
Dulaglutide
Exenatide
Liraglutide
Lixisenatide
Orforglipron
§
Semaglutide
Taspoglutide
†
GLP1 poly-agonist peptides
Mazdutide
(GLP-1/
GCGR
)
Retatrutide
§
(GLP-1/GIP/GCGR)
Tirzepatide
(GLP-1/GIP)
DPP-4 inhibitors
/"gliptins"
Alogliptin
Anagliptin
Evogliptin
Garvagliptin
Gemigliptin
Gosogliptin
Linagliptin
Melogliptin
Omarigliptin
Saxagliptin
Sitagliptin
Teneligliptin
Trelagliptin
Vildagliptin
Other
Aldose reductase inhibitors
Epalrestat
Fidarestat
§
Ranirestat
†
Tolrestat
‡
Zenarestat
§
Alpha-glucosidase inhibitors
Acarbose
Miglitol
Voglibose
SGLT2 inhibitors
/"gliflozins"
Canagliflozin
Dapagliflozin
Empagliflozin
#
Ertugliflozin
Ipragliflozin
Luseogliflozin
Remogliflozin
§
Sergliflozin
§
Sotagliflozin
Tofogliflozin
†
Velagliflozin
Other
Benfluorex
‡
Bromocriptine
Imeglimin
Combinations
Alogliptin/metformin
Canagliflozin/metformin
Cagrilintide/semaglutide
§
Dapagliflozin/metformin
Dapagliflozin/saxagliptin
Dapagliflozin/saxagliptin/metformin
Empagliflozin/linagliptin
Empagliflozin/metformin
Gemigliptin/rosuvastatin
Glibenclamide (glyburide)/metformin
Glimepiride/rosiglitazone
Linagliptin/metformin
Metformin/acarbose
Metformin/ertugliflozin
Metformin/evogliptin
Metformin/gemigliptin
Metformin/repaglinide
Metformin/sulfonylureas
Metformin/teneligliptin
Phenformin/sulfonylureas
Pioglitazone/alogliptin
Pioglitazone/glimepiride
Pioglitazone/metformin
Pioglitazone/sitagliptin
Rosiglitazone/metformin
Saxagliptin/metformin
Sitagliptin/dapagliflozin
Sitagliptin/ertugliflozin
Sitagliptin/metformin
Sitagliptin/simvastatin
Vildagliptin/metformin
#
WHO-EM
‡
Withdrawn
from market
Clinical trials
:
†
Phase III
§
Never to phase III
v
t
e
Merck & Co., Inc.
Corporate directors
Richard Clark
Johnnetta Cole
William Harrison
William Kelley
Rochelle Lazarus
Thomas Shenk
Anne Tatlock
Samuel Thier
Wendell Weeks
Peter Wendell
Subsidiaries
Acceleron Pharma
Cubist Pharmaceuticals
H. K. Mulford Company
Schering-Plough
Viralytics
Products
Alendronate
Aprepitant
Ertapenem
Ezetimibe
Ezetimibe/simvastatin
Finasteride
Fosaprepitant
Indinavir
Losartan
Lovastatin
Montelukast
Omarigliptin
Raltegravir
Rizatriptan
Rofecoxib
rVSV-ZEBOV vaccine
Simvastatin
Sitagliptin
Vericiguat
Vorinostat
Schering-Plough
Coppertone sign
Desloratadine
Ezetimibe
Ezetimibe/simvastatin
Famciclovir
Infliximab
Loratadine
Mometasone
Rocuronium bromide
Temozolomide
Tibolone
Urofollitropin
Facilities
Merck Headquarters Building
Publications
Merck Manual of Diagnosis and Therapy
The Merck Manuals
Index
Manual
Veterinary
Geriatrics
Portal
:
Medicine